GS-9620 treatment is associated with a reversible increase in serum liver enzymes and thrombocytopenia, and induction of intrahepatic CD8+ T cells, NK cells, B cells, and interferon response transcriptional signaling. Here, CD8A is linked to Thrombocytopenia.